share_log

Aegis Capital Reiterates Buy on Sunshine Biopharma, Maintains $15 Price Target

Benzinga ·  Dec 6 00:37

Aegis Capital analyst David Bouchey reiterates Sunshine Biopharma (NASDAQ:SBFM) with a Buy and maintains $15 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment